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influencethe resulting dose distribution. In the present work, we study 
the effect of different reconstruction parameters on dose distribution 
for both dose painting by contours (DPC) and dose painting by 
numbers (DPBN) techniques.  
Materials and Methods: 18FDG-PET/CT was performed for 8 advanced 
stage non-small cell lung cancer patients on a Siemens Biograph 40 
PET/CT-scanner.For each patient, 6 different PET reconstructions 
were applied; ordered subsets expectation maximization (OSEM) with 
21 subsets, using 2 (OSEM2i), 3 (OSEM3i)and 4 (OSEM4i) iterations. In 
addition, the data was reconstructed using theSiemens HD PET 
algorithm that corrects for the varying point spread function(PSF) 
inside the scanner, with 21 subsets, 2 (PSF2i), 3(PSF3i) and 4 
(PSF4i)iterations. Gaussian post filtering was 5 mm for all cases. A 
GTV was generated for each patient, encompassing the primary lung 
tumor including all voxels with an SUV > 2.0 in the standard OSEM2i 
reconstruction.  
For DPC, a boost volume was defined as the 50% of SUVmax for each 
reconstruction[1]. The boost volumes were assigned doses 
corresponding to an increase in mean GTV dose from 60 to 70 Gy. For 
each boost volume the quality factor (QF) [2] of the dose distribution 
was calculated with reference to the standard reconstruction as well 
as differences in boost volumes. For DPBN, a boost dose was 
distributed ranging from 60 to 130 Gy within the GTV assuming a 
linear relationship between FDG voxel intensity and prescribed dose 
distribution [2],using SUVmax as threshold for voxels receiving 
maximum dose. Dose volume histograms (DVH) were extracted for all 
reconstructions, as well as quality factors (QF) compared to the 
standard reconstruction OSEM2i.  
Results: For DPC, the mean boost volume was 32 ± 9 % and 31 ± 9 % of 
the GTV for OSEM2i and PSF2i, respectively. Correspondingly, the 
mean dose to the boost volume was 91 ± 10 Gyand 95 ± 13 Gy for 
OSEM2i and PSF2i. Considering the different reconstructions, the 
largest observed mean difference in boost volume was -11 ± 6 %, 
between OSEM4i and PSF2i. The mean difference in boost volume for 
OSEM2i and PSF2i was -9 ± 6%. The largest mean QF was 2.1 %, for 
PSF2i.  
For DPBN, for all patients except one, DVHs of the different 
reconstructions were approximately similar. The mean dose to the 
GTV was 81 ± 4 Gy and 80 ± 4 Gy for OSEM2i andPSF2i, respectively. 
The mean QF ofPSF2i relative to OSEM2i was 1.8 ± 0.8 %.  
Conclusions: PET reconstruction settings have an effect on PET-boost 
dose distributions, although the effect is small or moderate for most 
patients.  
[1] van Elmpt, W., De Ruysscher,D., van der Salm, A., et al. Radiother 
Oncol 2012; 104: 67-71. 
[2]Vanderstraten B,De Gersem W, Derie C, et al. Radiother Oncol 
2006; 79; 249-258 
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Purpose/Objective: Pareto front navigation, lexicographic ordering 
and other methods have been suggested to organize, guide and 
accelerate the dose optimization process. These methods are 
currently only feasible for the optimization of fluence weight profiles 
because the optimization of deliverable treatment plans adds greatly 
to their complexity. Thus, it is frequently not possible to maintain the 
carefully established balance between various treatment goals in leaf 
segmentation. We address the problem how a Pareto-optimal dose 
distribution can be preserved throughout the entire optimization, and 
replicated by a deliverable leaf sequence for VMAT or dMLC-IMRT, 
computed with the final dose algorithm. 
Materials and Methods: The method comprises 4 elements: 1) during 
the optimization of fluence profiles, a complimentary set of 
smoothing penalties and novel projection operators prevent 
undeliverable fluence distributions.This minimizes the quality loss due 
to leaf sequencing. 2) once the final dose distribution has been 
accepted, a multitude of features of the DVHs of targets and organs 
are captured in facsimile cost functions and their values recorded as 
reference. 3) after sequencing for VMAT or dMLC-IMRT and dose 
computation with the final algorithm, the leaf positions are iteratively 
adjusted in order to reproduce the previously determined facsimile 
cost function values. 4) as a final resort, the case that the Pareto-
optimum dose distribution cannot be replicated is detected 
automatically, and facsimile cost functions are relaxed in the order of 
the user´s preference, starting with the least significant. The user 
preference is recorded in the initial plan selection process. 
The method was implemented in the research version of a commercial 
planning system. Treatment plans were generated for 6 case classes 
comprising a minimum of 5 patients each. 
Results: Across all case classes, in 92% of cases the quality of the 
Pareto-optimum dose could be replicated or exceeded, but only if the 
following prerequisites were given: 1) the associated fluence profiles 
need to be subjected to rigorous smoothness and deliverability 
constraints so that the plan navigation is not performed on illusionary 
dose distributions. By the same token, the expert can also avoid 
making choices that cannot be realistically delivered. 2) the facsimile 
cost functions need to be organ- and target-specific, simple physical 
similarity measures either under-define (if too few are used) or over-
constrain (if too rigorous ones are used) the leaf sequence 
optimization. 3) for the leaf position optimization, the facsimile cost 
functions need to be treated as hard constraints, not as weighted 
objectives, to guarantee precise replication. 
Conclusions: The presented method replicates the quality of Pareto-
optimum dose distributions with deliverable plans, and thereby 
removes the need to consider highly complex delivery constraints 
during manual solution navigation.  
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Purpose/Objective: Aim of this study is to evaluate the performance 
of 5mm Millennium MLC and compare to a 2.5mm High Definition MLC 
for the treatment of Lung lesions using Volumetric Modulated Arc 
Therapy (VMAT) based Stereotactic Body Radiotherapy(SBRT). 
Materials and Methods: 10 Lung patients treated with SBRT at our 
institute were retrospectively planned with 5mm MMLC & 2.5mm 
HDMLC using VMAT technique. The gross tumor volume ranged from 
2.2 cm3 to 151 cm3. All these patients were treated with 5mm MMLC 
and hence 5mm MMLC plans were kept as reference. The reference 
plans were re-optimized and recomputed with identical planning 
parameters for 2.5 mm HDMLC system. Dose computation was 
performed using AcurosXB Advance dose calculation algorithm in 
Eclipse treatment planning system(Version 10) with tissue in-
homogeneity taken into account. Each plan was normalized such that 
95% of the planning target volume (PTV) receives 100% of the 
prescribed dose. Plan evaluation was performed using figures of 
merit for a rapid and objective assessment on the quality of two 
treatment plans for MMLC & HDMLC. For PTV conformity index (CI), 
Heterogeneity index (HI) were used to quantify the quality whereas 
for normal tissues, Gradient index (GI) defined as ratio of 50 % Isodose 
volume to the prescription Isodose volume & D25(25 % Isodose volume) 
were used. Planning objectives were based on RTOG 0915 guidelines. 
Results: Both the MLC meet the RTOG criteria for the CI and HI. As 
shown in the table-1 the CI range was from 1.07 (151 cm3) to 1.38 (2.2 
cm3) with median of 1.14 + 0.10 for HDMLC & 1.07 (151 cm3) - 
1.44(2.2 cm3) with median of 1.15+ 0.12 for MMLC. For normal tissues 
the GI ranges from 3.61 (151 cm3) to 6.14 (2.2 cm3)as compared to 
3.67 (151 cm3) to 7.22(2.2 cm3) for HDMLC & MMLC respectively. 
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PTV 
volume 
cm3 
Conformity 
Index 
Heterogeneity 
Index 
D25% cc Gradient 
Index 
HD MMLC Diff 
% 
HD MMLC HD MMLC Diff 
% 
HD MMLC 
2.20 1.38 1.44 4.46 0.18 0.18 53.30 67.70 21.27 6.14 7.27 
4.10 1.30 1.33 2.05 0.21 0.22 102.98 117.77 12.56 5.64 6.34 
10.10 1.22 1.25 2.96 0.18 0.18 241.20 266.80 9.59 5.20 5.55 
16.30 1.19 1.21 1.75 0.21 0.22 346.32 374.68 7.57 4.68 5.02 
24.70 1.16 1.17 1.39 0.23 0.24 488.50 526.50 7.22 4.38 4.66 
39.30 1.14 1.14 0.00 0.27 0.26 690.98 722.64 4.38 4.02 4.17 
57.10 1.11 1.11 0.01 0.24 0.24 954.97 1001.77 4.67 3.97 4.11 
71.80 1.09 1.09 0.00 0.20 0.21 1111.70 1126.10 1.28 3.77 3.94 
92.00 1.10 1.10 0.00 0.24 0.24 1333.96 1355.50 1.59 3.72 3.87 
119.80 1.08 1.08 0.00 0.22 0.25 1604.90 1655.35 3.05 3.68 3.84 
151.00 1.07 1.07 0.00 0.17 0.20 1893.40 1936.68 2.23 3.61 3.67 
 
Conclusions: Data derived from this dosimetric study showed that 
both the MLC systems very well satisfy the RTOG 0915 guidelines in 
terms of CI as well as GI. In-depth analysis showed that there was a 
marginal benefit in terms of both CI as well as GI with HDMLC over 
MMLC in PTV volume less than 4cc. However clinical significance of 
this marginal benefit warrants further investigation in order to find 
out whether these small dosimetric advantages can narrate into 
clinical outcome. Further the institutions who has only 5mm MMLC can 
still do SBRT as the results showed that it can very well satisfy RTOG 
criteria and match HDMLC provided the volume of PTV is greater than 
4cc. 
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Purpose/Objective: A method was developed to automate RT 
treatment planning for Head and Neck (H&N) cancer in order to 
reduce workload and create consistency in the RT treatment planning 
procedure. 
Materials and Methods: For a group of 8 patients (2 oropharynx, 3 
hypopharynx, 3 larynx), we developed scripts to generate treatment 
plans based on manual delineations of the organs at risk (OARs) and 
PTV. In this planning study we focus on VMAT treatment planning for 
H&N patients, where we consider the elective RT in a sequential 
treatment with a prescribed dose of 23 x 2Gy. For treatment planning 
the Pinnacle3 treatment planning system was used, in combination 
with the native scripting language and Python. We generated 6MV dual 
arc (178-182°) VMAT treatment plans, using the Pinnacle3 SmartArc 
optimization module. The automated method consists of a first 
optimization round using objectives solely on the PTV (Min and Max 
Dose), whole body, brainstem and spinal cord (Max Dose). In a second 
optimization round the objectives for the remaining OARs are 
introduced: base of tongue, constructor muscle, larynx, oral cavity 
and parotid glands. In 5 successive optimization rounds the mean dose 
objectives for these OARs were systematically lowered, by setting an 
objective to reduce the mean dose to the OARs by 1 Gy compared to 
the achieved dose for the latest optimization round, if the score of 
the penalty function was below 10-6. For a fair comparison, all 
treatment plans were automatically prescribed to a PTV coverage of 
V95%=99%. The automatically generated treatment plans (ATPs) were 
evaluated on the dose levels in the OARs, and compared with the 
manually generated clinical treatment plans (CTPs). 
Results: For 6 out of 8 ATPs, the clinical constraints on the OARs (Dmax 
Brainstem, Dmean Base of Tongue, etc … see table) and volume of the 
PTV receiving a high dose (V107%<1%) were met for all ATPs, if they 
were met for the corresponding CTP. In the remaining 2 plans the 
volume of the PTV receiving a high dose was considered unacceptable 
(V107%>>1%) and these plans were not further analyzed. The 
differences in the clinical parameters between the accepted ATP and 
CTP were not significant. These treatment plans are therefore 
considered adequate. This technique can be applied to generate a 
good starting point for clinical treatment plans. However, it remains 
essential that generated ATPs are carefully evaluated by an 
experienced dosimetrist, and that the RT plan is adapted when 
necessary. 
  
 ATP-CTP(sd), Gy) 
Dmax Brainstem -0.4 (2.1) 
Dmean Base of Tongue -0.9 (1.3) 
Dmean Constructor muscle 0.1 (0.8) 
Dmean Larynx 0.3 (0.8) 
Dmean Oral cavity -1.5 (3.6) 
Dmean contralateral parotid gland -0.6 (1.2) 
Dmean ipsilateral parotid gland 1.4 (2.2) 
D1% Spinal cord -0.5 (1.7) 
Table: Average difference in dose levels for OARs in the H&N region 
between the clinical treatment plan (CTP) and automatic treatment 
plan (ATP). The value in parentheses indicates the standard deviation.  
 
Conclusions: Using an automated method for generating VMAT 
treatment plans for H&N cancer, we were able to generate adequate 
treatment plans for 6 out of the 8 considered patients.  
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Purpose/Objective: Lung SBRT has emerged as a promising technique 
to treat early stage lung cancer patients with medically inoperable 
disease and for patients who refuse surgery when using biologically 
effective doses in excess of 100 Gy10. The delivery techniques that 
have been proposed vary in terms of ability to meet treatment 
planning criteria, delivery accuracy and estimated treatment times. 
The purpose of this study is to evaluate coplanar VMAT (C-VMAT), non-
coplanar VMAT (NC-VMAT) and non-coplanar IMRT (NC-IMRT) in terms 
of ability to meet planning criteria, dosimetric accuracy of delivery 
and beam-on time. 
Materials and Methods: There were 18 cases that were identified as 
patients who would have been eligible to enrol on our in-house SBRT 
protocol. Each case had 3 unique treatment plans created: C-VMAT, 
NC-VMAT and NC-IMRT. C-VMAT plans consisted of 2 coplanar 360 
degree arcs. NC-VMAT consisted of a single coplanar 360 degree arc 
and a 90 degree non-coplanar arc created for a couch rotation of 90 
degrees. NC-IMRT consisted of 7 equally spaced co-planar beams and 4 
beams delivered for a couch rotation of 90 degrees. Treatment plans 
were planned with Pinnacle v9 (Philips Medical Systems, Andover, MA, 
USA) and attempted to meet planning goals set out with our in-house 
protocol which was adapted from the British Columbia provincial lung 
SBRT guidelines. All plans were delivered to the ArcCheck device (Sun 
Nuclear Corporation, Melbourne, FL, USA) where both delivery 
accuracy and beam-on time was evaluated. 
Results: Treatment planning criteria can be sub-divided into PTV 
criteria and OAR criteria. For the PTV criteria, all plans were able to 
meet the prescription criteria and high dose spillage criteria however 
the low dose spillage criteria (i.e. ratio of 50% isovolume to PTV) had 
minor deviations for 11/18 C-VMAT plans and 3/18 for both NC-VMAT 
and NC-IMRT plans. For OARs, all plans performed equally well for 
sparing OARs and the inability to meet planning criteria was largely 
due to OAR overlap with the PTV which occurred for ribs in 12/18 
cases, for heart in 3/18 cases and for the great vessels in 2/18 cases. 
The mean lung dose, V20, V10, V5 and V2 were very similar across all 
delivery techniques. The ArcCheck delivery accuracy as evaluated by 
gamma(2%,2 mm) for all 18 cases was 92.6±3.7%for C-VMAT, 
96.6±2.1% for NC-VMAT and 95.1±2.1% for NC-IMRT. The treatment 
times were ~5.0 minutes for C-VMAT, ~7.0 minutes for NC-VMAT and 
~12.5 minutes for NC-IMRT. 
Conclusions: All three treatment techniques were deemed to be 
clinically acceptable by two lung radiation oncologists in terms of plan 
quality, delivery accuracy and treatment times. The main trade-offs 
identified in this study were that C-VMAT produced plans with shorter 
beam-on times while sacrificing conformity for the low dose spillage 
volume.  
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